NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.